Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (20472)	7/11/2006 1:28:53 PM
From: former_pgs	Read Replies (2) \| Respond to of 52153

CRME: >But Rodman & Renshaw analyst Michael King said RSD1235 has the "most attractive safety and efficacy profile of any AF agent to date"< This is not true. RSD1235 actually delivers a lower rate of conversion (ie. efficacy) than electric cardioversion. The trade-off is whether an IV agent is more convenient / preferable as compared to the mild sedation that accompanies cardioversion. FWIW, where I work, there isn't much that is holding docs back from using cardioversion.